Scienture Stock Set to Reverse Split on Monday, October 5th (NASDAQ:SCNX)

Scienture Holdings, Inc. (NASDAQ:SCNX) shares are set to reverse split on Monday, October 5th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, October 4th.

Scienture Price Performance

SCNX traded down $0.08 during trading on Thursday, reaching $0.18. The company had a trading volume of 1,900,908 shares, compared to its average volume of 1,572,648. The company has a quick ratio of 2.97, a current ratio of 3.04 and a debt-to-equity ratio of 0.15. The business has a 50 day simple moving average of $0.37 and a 200-day simple moving average of $0.38. Scienture has a 52 week low of $0.18 and a 52 week high of $2.60.

Scienture (NASDAQ:SCNX) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. The firm had revenue of $0.34 million for the quarter, compared to the consensus estimate of $1.96 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Scienture in a report on Monday, September 21st. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Scienture has a consensus rating of “Hold” and an average price target of $1.50.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Scienture stock. Susquehanna International Group LLP purchased a new position in shares of Scienture Holdings, Inc. (NASDAQ:SCNX) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned approximately 0.57% of Scienture at the end of the most recent quarter. Institutional investors own 5.68% of the company’s stock.

About Scienture

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).